Powder: -20°C for 3 years | In solvent: -80°C for 1 year
S19-1035 is a potent and specific inhibitor of aldo-keto reductase 1C3 (AKR1C3), displaying an inhibitory concentration (IC50) of 3.04 nM. It is primarily utilized in tumor research.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 55.00 | |
10 mg | In stock | $ 84.00 | |
25 mg | In stock | $ 172.00 | |
50 mg | In stock | $ 278.00 | |
100 mg | In stock | $ 452.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 61.00 |
Description | S19-1035 is a potent and specific inhibitor of aldo-keto reductase 1C3 (AKR1C3), displaying an inhibitory concentration (IC50) of 3.04 nM. It is primarily utilized in tumor research. |
Targets&IC50 | AKR1C3:3.04 nM |
In vitro |
S19-1035 demonstrates low cytotoxicity (0-100 μM ; 72 h or 96 h) and limited antitumor efficacy when used alone.[1] S19-1035 significantly reverses the resistance of doxorubicin-resistant breast cancer cell lines when administered at 10 μM for 8 days.[1] |
In vivo | Setrobuvir (200, 400, and 800 mg) BID were -2.1, -2.2, and -2.9 log10 IU/mL, respectively (vs ≤0.1 log10 IU/mL with placebo).[3] |
Molecular Weight | 356.80 |
Formula | C19H17ClN2O3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 112.5 mg/mL (315.3 mM), Sonication and heating to 60℃ are recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
S19-1035 Metabolism NADPH inhibitor inhibit